Matthew Mace and Mike Anselmo highlight the necessity of understanding the reimbursement landscape when developing medical devices. The episode sheds light on the intricacies of gaining market access beyond FDA approval, focusing on how new medical technologies must prove their economic value. Anselmo explains the critical role of the AMA in managing reimbursement codes and how companies must strategically align their clinical trials to demonstrate value to payers and providers alike. This discussion underscores the importance of a comprehensive commercialization strategy that addresses not just approval but also the financial realities of healthcare innovation.